ClinicalTrials.gg
RecruitingNCT07585097Updated Oct 23, 2026

A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

An observational study in Alagille Syndrome, sponsored by Ipsen. Recruiting at 14 sites in 2 countries. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ipsen · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 23, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Ages
6 Months and older
Sex
All
01

Study summary

This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.

The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.

02

Conditions studied

  • Alagille Syndrome

Browse trials for

03

In context

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

This study's planned enrollment of 30 is below the median of 120 across 15 observational studies indexed under Alagille Syndrome.

Browse Alagille Syndrome studies →

Lead sponsor

Ipsen is the lead sponsor of 291 studies on the registry; 19 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with Alagille syndrome (ALGS) who have been prescribed odevixibat by their treating physician will be enrolled into the study. Participants who started odevixibat treatment before study implementation may also be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with ALGS.
  • On (or starting) active odevixibat treatment.
  • Aged 6 months or older at the time of consent.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in a clinical trial with odevixibat.
  • Currently participating in any interventional clinical trial for ALGS.
  • Have any to odevixibat as per the locally approved label.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Percentage of participants experiencing adverse events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered odevixibat, whether or not considered related to treatment.

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  2. Percentage of participants experiencing serious adverse events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered odevixibat, whether or not considered related to treatment.

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

Secondary outcomes

  1. Percentage of participants with severe diarrhoea events

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  2. Percentage of participants with bloody diarrhoea events

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  3. Percentage of participants experiencing diarrhoea events with concurrent dehydration

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  4. Percentage of participants experiencing diarrhoea events treated with oral or intravenous rehydration

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  5. Change from baseline in fat-soluble vitamin (FSV) levels

    Time frame: From baseline and up to end of data collection (approximately 5 years of data collection)

  6. Percentage of participants with fat-soluble vitamin deficiency

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  7. Percentage of participants with clinical manifestations of fat-soluble vitamin deficiency

    For example, bleeding, rickets, or osteopenia.

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  8. Percentage of participants with suspected hepatotoxicity requiring interruption of odevixibat treatment

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  9. Percentage of participants with clinical manifestations related to hepatotoxicity

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  10. Change from baseline in alanine aminotransferase (ALT)

    Time frame: From baseline and up to end of data collection (approximately 5 years of data collection)

  11. Change from baseline in aspartate aminotransferase (AST)

    Time frame: From baseline and up to end of data collection (approximately 5 years of data collection)

  12. Change from baseline in gamma-glutamyl transferase (GGT)

    Time frame: From baseline and up to end of data collection (approximately 5 years of data collection)

  13. Change from baseline in blood bilirubin

    Time frame: From baseline and up to end of data collection (approximately 5 years of data collection)

  14. Change from baseline in international normalized ratio (INR)

    Time frame: From baseline and up to end of data collection (approximately 5 years of data collection)

  15. Percentage of participants with hospitalisations due to diarrhoea

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  16. Percentage of participants with hospitalisations due to hepatotoxicity

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  17. Percentage of participants with hospitalisations due to fat-soluble vitamin deficiency

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  18. Percentage of participants with treatment discontinuations due to diarrhoea

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection).

  19. Percentage of participants with treatment discontinuations due to hepatotoxicity

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection).

  20. Percentage of participants with treatment discontinuations due to fat-soluble vitamin deficiency

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection).

  21. Percentage of participants with pregnancy and maternal complications

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  22. Percentage of foetuses, neonates, or infants with adverse effects following exposure to odevixibat during pregnancy and/or lactation

    Time frame: From first documented exposure during pregnancy or lactation and up to end of data collection (approximately 5 years of data collection)

  23. Percentage of participants with biliary diversion surgery

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  24. Percentage of participants with liver transplantation

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  25. Percentage of participants who die from any cause

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

  26. Percentage of participants switching from odevixibat to maralixibat

    Time frame: From first ICF signature and up to end of data collection (approximately 5 years of data collection)

07

Study locations

3 of 14 sites recruiting
  • Hospices Civils de Lyon - Hopital Femme Mere Enfant
    Bron, France
    Recruiting
  • CHU Dijon Bourgogne
    Dijon, France
    Not yet recruiting
  • APHP - Hopital Bicetre - Paris Sud
    Le Kremlin-Bicêtre, France
    Not yet recruiting
  • APHM - CHU Timone
    Marseille, France
    Not yet recruiting
  • CHU de Montpellier - Hopital Saint Eloi
    Montpellier, France
    Not yet recruiting
  • APHP - Hopital Necker-Enfants Malades
    Paris, France
    Not yet recruiting
  • CHU de Toulouse - Hopital Paule de Viguier
    Toulouse, France
    Not yet recruiting
  • APHP - Centre Hepato-Biliaire Hospital Paul Brousse
    Villejuif, France
    Not yet recruiting
  • Azienda Ospedaliero Universitaria Meyer
    Florence, Italy
    Recruiting
  • Azienda Ospedaliera Di Rilievo Nazionale Santobono Pausilipon
    Naples, Italy
    Recruiting
  • University Hospital Of Padova
    Padova, Italy
    Not yet recruiting
  • IRCCS Ospedale Pediatrico Bambino Gesu
    Roma, Italy
    Not yet recruiting
  • A.O.U. Citta della Salute e della Scienza di Torino - Ospedale Infantile Regina Margherita
    Torino, Italy
    Not yet recruiting
  • Ospedale Universitario Di Udine
    Udine, Italy
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Sep 2031, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 13, 2026
StartActual
Jul 10, 2026
Primary completionEst.
Sep 30, 2031
CompletionEst.
Sep 30, 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Azienda Ospedaliera Di Rilievo Nazionale Santobono Pausilipon · Naples, ItalyNot yet recruiting→Recruiting
  • Hospices Civils de Lyon - Hopital Femme Mere Enfant · Bron, FranceNot yet recruiting→Recruiting
across 2 updates, Oct 1, 2026 – Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Hospices Civils de Lyon - Hopital Femme Mere Enfant is now Recruiting
    + 1 other change: verification date
  2. Oct 1, 2026
    Azienda Ospedaliera Di Rilievo Nazionale Santobono Pausilipon is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07585097
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Jul 10, 2026
Primary completion
Sep 30, 2031 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Ipsen Clinical Study Enquiries
Contact
clinical.trials@ipsen.com
See e mail
Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion